Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
19 janv. 2023 06h00 HE | InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets...
22157.jpg
Outlook on the Myasthenia Gravis Diagnosis and Treatment Global Market to 2028 - Featuring Avadel Pharmaceuticals, Bausch Health Companies, Baxter International and CSL Behring Among Others
05 janv. 2023 06h58 HE | Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
29 déc. 2022 12h09 HE | AB Science
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE...
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier l’étude confirmatoire de Phase 3 avec le masitinib dans le traitement des formes progressives de la sclérose en plaques
29 déc. 2022 12h09 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER L’ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DES FORMES...
Linda E. Cardinale MS Center and Sordoni Partnership
Sordoni Golf Outing Raises $40,000 for the Linda E. Cardinale Multiple Sclerosis Center
13 oct. 2022 11h30 HE | Sordoni Construction Co.
BEDMINSTER, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sordoni Construction Co., a Bedminster-based construction management company, recently donated $40,000 to The Linda E. Cardinale Multiple...
Vantage Market Research.png
Multiple Sclerosis (MS) Drugs Market Size to Hit Sales of $31.2 Bn by 2028 | Biogen, Novartis, and Roche Hold Over 55% Share of Multiple Sclerosis Drugs
11 oct. 2022 04h10 HE | Vantage Market Research
WASHINGTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Global multiple sclerosis drugs market size was $25.1 Billion in 2021 and is estimated to generate revenue of $31.2 Billion by 2028 at a CAGR of 3.7%...
AMR Logo.png
Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
27 sept. 2022 12h00 HE | Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
Figure 1
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
20 sept. 2022 12h47 HE | Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Figure 1
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
07 sept. 2022 12h37 HE | Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Figure 1
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
30 août 2022 10h37 HE | Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...